Form D · Other Health Care
Ovid Therapeutics Inc.
New York, NY · CIK 0001636651
Offering snapshot reported Jan 20, 2017 · SEC filing
- Reported sold
- $25.9M Offering amount: $25.9M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 6, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 20, 2017 | Initial | $25,861,228 | No comparison | 1 | SEC filing |
| Aug 18, 2015 | Initial | $74,999,893 | No comparison | 50 | SEC filing |
| Mar 18, 2015 | Initial | $5,060,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-278877
Source: Form D, filed Jan 20, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Karen Bernstein | Director |
| Matthew J. During | Director, Executive |
| Mark Feldberg | Director |
| Bart Friedman | Director |
| Jeremy M. Levin | Director, Executive |
| Amit Rakhit | Executive |
| Yaron Werber | Executive |
| Douglas E. Williams | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
1460 Broadway Suite 15021
New York, NY, 10036
New York, NY, 10036